Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-019329
Filing Date
2025-07-03
Accepted
2025-07-03 16:30:17
Documents
2
Period of Report
2025-06-26

Document Format Files

Seq Description Document Type Size
1 form3-07032025_080709.html 3  
1 form3-07032025_080709.xml 3 1659
2 ex24-07032025_080710.htm EX-24 4815
  Complete submission text file 0001415889-25-019329.txt   8188
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 2 SNUNIT STREET SCIENCE PARK, P.O. BOX 455 CARMIEL Israel 2161401
Business Address
Elze Christian (Reporting) CIK: 0002075661 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33357 | Film No.: 251105928